The PCAST Report on Pharmaceutical Innovation: Implications for the FDA

被引：11

作者：

Woodcock, J. ^{[1
]}

机构：

[1] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 94卷 / 03期

关键词：

D O I：

10.1038/clpt.2013.88

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In September 2012, the President's Council of Advisors on Science and Technology (PCAST) released the report"Propelling Innovation in Drug Discovery, Development and Evaluation:" A product of discussions with many stakeholders, the report reiterates current problems in drug development, including diminished return on basic biomedical research. The report calls for doubling the current annual output of innovative new medicines- an ambitious goal. Recommendations and resulting initiatives will probably affect the FDA's drug regulatory programs.

引用

页码：297 / 300

页数：4

共 7 条

[1]

[Anonymous], CLIN TRIAL WOM NEWL

[2]

[Anonymous], PROP INN DRUG DISC D

[3] Reengineering Translational Science: The Time Is Right [J].

Collins, Francis S. .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (90)

[4]

National Institutes of Health, 2011, JOINT NIH IND TARG V

[5]

US Department of Health and Human Services Food and Drug Administration, 2004, INN STAGN CHALL OPP

[6]

US Food and Drug Administration, 2013, BIOM QUAL PROGR

[7]

US Food and Drug Administration, 2013, FDA SENT IN

← 1 →